Interim report from Science Invest

Sweden's A* Science Invest AB, which was formed in October 1997, saysthat a multitude of projects and project ideas, mainly from the country's Goteborg University, have now been evaluated, acquired, considerably refined, further documented and developed by A*, successfully creating increased value.

Among these are: - a license agreement on the development of a novel treatment for Helicobacter pylori signed with Carbion OY; - the future development of novel medications in the area of dyspepsia and inflammatory bowel syndrome, which has been transferred to associate Pharmacore AB; - projects regarding cell manipulation and measurements, which will be passed to Cellectricon AB; stem-cell activities. which will be transferred to the newly-formed Cell Therapeutics (Scandinavia); - the planned initiation of in vitro and animal studies in cancer and diabetes projects; - and the start of clinical studies in sciatica, obstructive sleep apnoea and diabetes projects.